Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) has received a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among […]